The Association of the British Pharmaceutical Industry
Medicines are transforming our lives like never before.
We want the UK to be the best place in the world to research, develop and use the medicines and vaccines of the future.
- Valuing and accessing medicines
- RESEARCH, DEVELOPMENT AND MANUFACTURING
- WORKING IN PARTNERSHIP
- Industry Reputation
- International Policy, Trade & IP
- Health Data
Valuing and accessing medicines
Ensuring value, access and uptake of innovative medicines and vaccines, now and in the future
Medicines bring huge value to NHS patients. The development of new medicines is uncertain, costly, and involves significant rates of failure. The pharmaceutical industry spends $160 billion per year on research and development.The private sector produces nearly all the medicines and vaccines available to us. Companies need to make a profit – and a return – on global investment in order to maintain investment in the next generation of medicines.
RESEARCH, DEVELOPMENT AND MANUFACTURING
Improving the UK's attractiveness for industry, research, development and manufacturing
We're helping to build a thriving environment for medicine discovery so the UK can be the best place in the world to research and develop new medicines and vaccines.
WORKING IN PARTNERSHIP
Building better partnerships between industry and NHS and across the Life Sciences sector
We have a long-standing positive relationship with the NHS, and a record of facilitate the same across various parties across the Life Sciences sector. We believe in focusing collaboration on where it can add the most value in making innovation as widely available to patients as possible.
Industry Reputation
Building a stronger industry reputation in the UK
Everywhere, every day someone relies on the results of our work to ensure their health and wellbeing. We are proud of this and are committed to working with a wide range of people - patients, doctors, nurses, regulators and governments - in order to deliver medicines in an ethically responsible way. Patients are at the heart of everything that we do.
International Policy, Trade & IP
Providing international leadership and driving global policy
The ABPI is working to ensure that the UK has the best relationship with our international partners for patients, public health and the life sciences sector.
Health Data
Improving the UK's health data capability and industry's access to data
We aim to harness the UK’s health data to support the efficient design, feasibility, recruitment and conduct of the full range of clinical trials. We are helping the UK make the most of health-related data for future research and development into new medicines.
Latest news
ABPI response to NICE review
The National Institute for Health and Care Excellence (NICE) looks set to approve changes to the way it evaluates new medicines and health technologies.
Pharmaceutical industry sets out manifesto for the next Northern Ireland Assembly
The pharmaceutical industry has set out five recommendations for the next Northern Ireland Assembly to deliver better health and care for patients, recover from the pandemic and deliver economic and jobs growth over the next term.
Gilead Sciences joins the ABPI
Gilead Sciences has joined the membership of the Association of the British Pharmaceutical Industry, effective from January 2022.
UK pharmaceutical industry welcomes India trade talks
The UK has published its negotiating objectives and announced the start of trade talks with India.
Latest blogs and events
Antibiotic resistance: A global, silent pandemic that is solvable
ABPI President Ben Osborn explains the problem of antibiotic resistance and what we can do about it.
Invest and innovate to keep UK life sciences globally competitive
Richard Torbett outlines the case for investing in our sector ahead of the autumn's Comprehensive Spending Review.
ABPI response to NICE review
The National Institute for Health and Care Excellence (NICE) looks set to approve changes to the way it evaluates new medicines and health technologies.
Pharmaceutical industry sets out manifesto for the next Northern Ireland Assembly
The pharmaceutical industry has set out five recommendations for the next Northern Ireland Assembly to deliver better health and care for patients, recover from the pandemic and deliver economic and jobs growth over the next term.
Key content hubs
The COP26 summit will bring parties together to accelerate action towards the goals of the Paris Agreement and the UN Framework Convention on Climate Change.
As a critical part of the health care community in the UK, the pharmaceutical industry wants to play the biggest possible role in the response to COVID-19.
The ABPI Code of Practice sets out the requirements the industry must comply with and supports companies’ commitment to self-regulation and to operate in a professional, ethical and transparent manner.
Rare diseases have a devastating impact on people’s lives: pharmaceutical companies here in the UK and around the world are working to change that – developing new medicines to give families hope for the future.
Very proud to be partners with @NIHR_Industry again in sponsoring this award open to amazing clinical research teams. 👇 https://t.co/qLhevqyXlh
— ABPI (@ABPI_UK) January 25, 2022
A clear legislative mandate for research can be delivered via Health & Care Bill amendments being debated today by Lord Sharkey and others. This will benefit patients, supporting levelling-up by addressing health inequalities: https://t.co/dKRwDSB7BC#ResearchActiveNHS pic.twitter.com/w4u6xSKQtM
— AMRC (@AMRC) January 24, 2022
🧵Today the House of Lords will discuss a Health and Care Bill amendment that would strengthen NHS workforce planning, resulting in independent assessments every two years for the staff needed to deliver future healthcare in England. pic.twitter.com/mxpp2yJlb8
— CRUK Policy (@CRUK_Policy) January 24, 2022
Join us at Pharma Sustainability Integrates for insights on how #pharma & #healthcare sector can take #COP26 forward, with input from leaders in the field Sir Jim McDonald, @UniStrathclyde Principal & VC & Ben Osborn, @ABPI_UK President & @Pfizer_UK MD https://t.co/yzyPtmCfnQ pic.twitter.com/r43I6zOlOX
— Life Science Integrates (@LSIntegrates) January 20, 2022
The Pharmaceutical Industry in the UK
![Turnover [1]](/media/n5lbxuf1/figures-turnover-36-7bn.jpg)
![R and D Investment [3]](/media/ouqnhlry/figures-r-d-investment-5-0bn.jpg)
Members
Online members portal (ABPI Meetings via Adam.ai)
ABPI members can log in for bespoke content and services.